Overview

Study of AT-752 in Patients With Dengue Infection

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials
Phase:
Phase 2
Details
Lead Sponsor:
Atea Pharmaceuticals, Inc.